Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
10 minute consultation [[electronic resource] ] : cardiovascular risk / / advisory board, Dr Jehad Aldegather ... [et al.]
| 10 minute consultation [[electronic resource] ] : cardiovascular risk / / advisory board, Dr Jehad Aldegather ... [et al.] |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | [Eng.], : Cedilla Publishing Ltd., c2010 |
| Descrizione fisica | 1 online resource (94 p.) |
| Disciplina | 616.1 |
| Altri autori (Persone) | AldegatherJehad |
| Collana | The 10-minute consultation |
| Soggetto topico |
Cardiovascular system - Diseases - Prevention
Cardiovascular system - Diseases - Risk factors |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-905982-11-9 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 9781905982110; Outside front cover; Conversion calculator; Title page; Copyright page; Contents; Foreword; Chapter 1 Introduction; Chapter 2 Who and what to test; Chapter 3 How to manage the patient at risk of CVD; Chapter 4 Person-centred care; Chapter 5 Applying the evidence; Chapter 6 Review and recall of the patient at risk of CVD; Further reading; Outside back cover |
| Record Nr. | UNINA-9910461975103321 |
| [Eng.], : Cedilla Publishing Ltd., c2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
10 minute consultation [[electronic resource] ] : cardiovascular risk / / advisory board, Dr Jehad Aldegather ... [et al.]
| 10 minute consultation [[electronic resource] ] : cardiovascular risk / / advisory board, Dr Jehad Aldegather ... [et al.] |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | [Eng.], : Cedilla Publishing Ltd., c2010 |
| Descrizione fisica | 1 online resource (94 p.) |
| Disciplina | 616.1 |
| Altri autori (Persone) | AldegatherJehad |
| Collana | The 10-minute consultation |
| Soggetto topico |
Cardiovascular system - Diseases - Prevention
Cardiovascular system - Diseases - Risk factors |
| ISBN | 1-905982-11-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 9781905982110; Outside front cover; Conversion calculator; Title page; Copyright page; Contents; Foreword; Chapter 1 Introduction; Chapter 2 Who and what to test; Chapter 3 How to manage the patient at risk of CVD; Chapter 4 Person-centred care; Chapter 5 Applying the evidence; Chapter 6 Review and recall of the patient at risk of CVD; Further reading; Outside back cover |
| Record Nr. | UNINA-9910786498103321 |
| [Eng.], : Cedilla Publishing Ltd., c2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antiplatelet therapy in cardiovascular disease / / edited by Ron Waksman, Paul A. Gurbel, Michael A. Gaglia, Jr
| Antiplatelet therapy in cardiovascular disease / / edited by Ron Waksman, Paul A. Gurbel, Michael A. Gaglia, Jr |
| Pubbl/distr/stampa | Chichester, West Sussex, United Kingdom : , : John Wiley & Sons, , 2014 |
| Descrizione fisica | 1 online resource (349 p.) |
| Disciplina | 616.1/061 |
| Soggetto topico |
Cardiovascular system - Diseases
Cardiovascular system - Diseases - Prevention |
| ISBN |
1-118-49402-4
1-118-49398-2 1-118-49401-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Antiplatelet Therapy in Cardiovascular Disease; Copyright; Contents; List of Contributors; Foreword; Preface; Section I Platelet Biology and Pathophysiology; 1 Platelet Pathophysiology and its Role in Thrombosis; Role of platelets during initiation of atherosclerosis and plaque formation; Role of platelets in thrombosis; References; 2 Platelet Receptors and Drug Targets: COX-1; Structure, expression, and catalytic activity of platelet COX-1; Functional role of platelet COX -1; Genetic polymorphisms of COX-1 and COX-2 expression in platelets
Platelet COX-1 as a target for antithrombotic therapyInteraction between aspirin and naNSAIDs at the level of platelet COX-1; In vitro and in vivo evidence for aspirin/naNSAID interaction; Concluding remarks; References; 3 Platelet Receptors and Drug Targets: P2Y12; P2 receptors; Roles of adenine nucleotides in platelet function; P2Y12; Conclusions; References; 4 Platelet Receptors and Drug Targets: GP IIb/IIIa; Introduction; Biology of the receptor; Glycoprotein IIb/IIIa receptor in platelet physiology; Platelet aggregation phase; "Inside-out" and "outside-in" GPIIb/IIIa signaling phenomenon Glycoprotein IIb/IIIa receptor and thrombus formationGlycoprotein IIb/IIIa receptor antagonists; Intravenous versus oral preparations: clinical aspects; Acknowledgment; References; 5 Platelet Receptors and Drug Targets: PAR1, Collagen, vWF, Thromboxane, and Other Novel Targets; Introduction; Protease-activated receptor 1 (PAR1); References; 6 Role of Inflammation and Hypercoagulability in Thrombosis; References; Section II Platelet Function Tests; 7 Light Transmission Aggregometry; Technique; References; 8 Vasodilator-Stimulated Phosphoprotein (VASP) Assay; Introduction; The VASP index assay VASP index and clinical eventsAlteration of antiplatelet therapy based on the VASP index; VASP index and new oral antiplatelet agents; Conclusions; References; 9 VerifyNow P2Y12 and Plateletworks Assays; Introduction; Verifynow P2Y12; Plateletworks; Validity of the test in measuring antiplatelet effect and its association with clinical outcomes; Conclusion; References; 10 Multiplate Analyzer; Historical background; Principles of the Multiplate® analyzer; Advantages; Disadvantages; Clinical studies in cardiovascular medicine; Studies in cardiovascular surgery Consensus definitions and cutoff values concerning platelet reactivitySummary; Acknowledgment; References; 11 Shear Stress-Based Platelet Function Tests; PFA-100; IMPACT-R; References; 12 Thrombelastography and Other Novel Techniques; Novel techniques; T2 magnetic resonance (T2MR); Shear-induced platelet aggregation assays; References; Section III Antiplatelet pharmacology; 13 Aspirin; Mode of antiplatelet action; Time dependency of inhibition of platelet function by aspirin; Dose-dependent inhibition of platelet function by aspirin; Negative interactions with other drugs Positive interactions with other drugs |
| Record Nr. | UNINA-9910140272703321 |
| Chichester, West Sussex, United Kingdom : , : John Wiley & Sons, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antiplatelet therapy in cardiovascular disease / / edited by Ron Waksman, Paul A. Gurbel, Michael A. Gaglia, Jr
| Antiplatelet therapy in cardiovascular disease / / edited by Ron Waksman, Paul A. Gurbel, Michael A. Gaglia, Jr |
| Pubbl/distr/stampa | Chichester, West Sussex, United Kingdom : , : John Wiley & Sons, , 2014 |
| Descrizione fisica | 1 online resource (349 p.) |
| Disciplina | 616.1/061 |
| Soggetto topico |
Cardiovascular system - Diseases
Cardiovascular system - Diseases - Prevention |
| ISBN |
1-118-49402-4
1-118-49398-2 1-118-49401-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Antiplatelet Therapy in Cardiovascular Disease; Copyright; Contents; List of Contributors; Foreword; Preface; Section I Platelet Biology and Pathophysiology; 1 Platelet Pathophysiology and its Role in Thrombosis; Role of platelets during initiation of atherosclerosis and plaque formation; Role of platelets in thrombosis; References; 2 Platelet Receptors and Drug Targets: COX-1; Structure, expression, and catalytic activity of platelet COX-1; Functional role of platelet COX -1; Genetic polymorphisms of COX-1 and COX-2 expression in platelets
Platelet COX-1 as a target for antithrombotic therapyInteraction between aspirin and naNSAIDs at the level of platelet COX-1; In vitro and in vivo evidence for aspirin/naNSAID interaction; Concluding remarks; References; 3 Platelet Receptors and Drug Targets: P2Y12; P2 receptors; Roles of adenine nucleotides in platelet function; P2Y12; Conclusions; References; 4 Platelet Receptors and Drug Targets: GP IIb/IIIa; Introduction; Biology of the receptor; Glycoprotein IIb/IIIa receptor in platelet physiology; Platelet aggregation phase; "Inside-out" and "outside-in" GPIIb/IIIa signaling phenomenon Glycoprotein IIb/IIIa receptor and thrombus formationGlycoprotein IIb/IIIa receptor antagonists; Intravenous versus oral preparations: clinical aspects; Acknowledgment; References; 5 Platelet Receptors and Drug Targets: PAR1, Collagen, vWF, Thromboxane, and Other Novel Targets; Introduction; Protease-activated receptor 1 (PAR1); References; 6 Role of Inflammation and Hypercoagulability in Thrombosis; References; Section II Platelet Function Tests; 7 Light Transmission Aggregometry; Technique; References; 8 Vasodilator-Stimulated Phosphoprotein (VASP) Assay; Introduction; The VASP index assay VASP index and clinical eventsAlteration of antiplatelet therapy based on the VASP index; VASP index and new oral antiplatelet agents; Conclusions; References; 9 VerifyNow P2Y12 and Plateletworks Assays; Introduction; Verifynow P2Y12; Plateletworks; Validity of the test in measuring antiplatelet effect and its association with clinical outcomes; Conclusion; References; 10 Multiplate Analyzer; Historical background; Principles of the Multiplate® analyzer; Advantages; Disadvantages; Clinical studies in cardiovascular medicine; Studies in cardiovascular surgery Consensus definitions and cutoff values concerning platelet reactivitySummary; Acknowledgment; References; 11 Shear Stress-Based Platelet Function Tests; PFA-100; IMPACT-R; References; 12 Thrombelastography and Other Novel Techniques; Novel techniques; T2 magnetic resonance (T2MR); Shear-induced platelet aggregation assays; References; Section III Antiplatelet pharmacology; 13 Aspirin; Mode of antiplatelet action; Time dependency of inhibition of platelet function by aspirin; Dose-dependent inhibition of platelet function by aspirin; Negative interactions with other drugs Positive interactions with other drugs |
| Record Nr. | UNINA-9910819754603321 |
| Chichester, West Sussex, United Kingdom : , : John Wiley & Sons, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ASPC manual of preventive cardiology / / editors, Nathan D. Wong, Ezra A. Amsterdam, and Roger S. Blumenthal
| ASPC manual of preventive cardiology / / editors, Nathan D. Wong, Ezra A. Amsterdam, and Roger S. Blumenthal |
| Pubbl/distr/stampa | New York : , : demosMEDICAL, , 2015 |
| Descrizione fisica | 1 online resource (295 p.) |
| Disciplina | 616.1/05 |
| Soggetto topico | Cardiovascular system - Diseases - Prevention |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-61705-141-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Title; Copyright; Contents; Contributors; Foreword; Preface; Acknowledgments; Share ASPC Manual of Preventive Cardiology; Chapter 1: National Burden of Cardiovascular Disease and Associated Risk Factors; Cardiovascular Disease; Mortality and Morbidity Attributable to CVD; Prevalence and Control of Cardiovascular Risk Factors; Subclinical Atherosclerosis; Ankle-Brachial Index; Economic Costs of Cardiovascular Disease; Summary; Acknowledgments; References; Chapter 2: Cardiovascular Risk Assessment; Rationale for Contemporary CV Risk Prediction
Relative Risk Versus Absolute Cardiovascular RiskTreatment Benefit Depends on Absolute Risk Rather Than Relative Risk; Multiple, Online Risk Prediction Tools for CVD are Widely Available; Current Guideline Recommendations; Current Clinical Practice Guidelines Suggest That the Indication and Intensity of Treatment Should Be Proportional to the Absolute Risk for CVD; Novel Developments in Global CVD Risk: Considering Alternative CVD Outcomes; Novel Developments in Global CVD Risk: Considering Alternative Risk Factors; Novel Serum Markers; Novel Imaging Markers; Other Risk Markers Novel Developments in Global CVD Risk: Considering Long-Term or Lifetime RiskConclusion; References; Chapter 3: The New American Prevention Guidelines: Aligning the Guidelines for Atherosclerotic Cardiovascular Risk Reduction With the Evidence; A New Approach; Major Themes; What You Need to Know; A. Heart Healthy Nutrition and Physical Activity Behaviors; B. Recommendations from the Risk Assessment Workgroup With Those Reflecting Expert Opinion Highlighted in Italics; C. Graded Recommendations for Statin Treatment to Reduce ASCVD Risk Footnotes to this Section (from the Cholesterol Guideline Report)Statin Safety Recommendations; Footnotes to this Section (from the Cholesterol Guideline Report); Monitoring Statin Therapy; Optimizing Statin Therapy; Insufficient Response to Statin Therapy; Footnotes to this Section (from the Cholesterol Guideline Report); Conclusions; References; Chapter 4: Management of High Blood Pressure; Epidemiology of Hypertension; Definition and Classification of Hypertension; Initial Evaluation of the Patient; Thresholds for Initiating Therapy; Lifestyle Modifications; Initial Drug Therapy Goal Blood Pressure for "Uncomplicated" Hypertensive PatientsGoal Blood Pressure for Hypertensive Patients with Other High-Risk Conditions; Other Issues; References; Chapter 5: Smoking and Passive Smoking; Smoking and Cardiovascular Disease; Secondhand Smoke; Trends in Cigarette Smoking; Prevention and Reduction of Tobacco Use Among Youth; Prevention and Cessation Programs for Adults; Cessation Strategies for Individuals; Behavioral Treatments; Pharmacologic Interventions; Clinical Approaches; Conclusions; References; Chapter 6: Metabolic Syndrome; History, Prevalence, and Epidemiology Definition |
| Record Nr. | UNINA-9910463373803321 |
| New York : , : demosMEDICAL, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ASPC manual of preventive cardiology / / editors, Nathan D. Wong, Ezra A. Amsterdam, and Roger S. Blumenthal
| ASPC manual of preventive cardiology / / editors, Nathan D. Wong, Ezra A. Amsterdam, and Roger S. Blumenthal |
| Pubbl/distr/stampa | New York : , : demosMEDICAL, , 2015 |
| Descrizione fisica | 1 online resource (295 p.) |
| Disciplina | 616.1/05 |
| Soggetto topico | Cardiovascular system - Diseases - Prevention |
| ISBN | 1-61705-141-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Title; Copyright; Contents; Contributors; Foreword; Preface; Acknowledgments; Share ASPC Manual of Preventive Cardiology; Chapter 1: National Burden of Cardiovascular Disease and Associated Risk Factors; Cardiovascular Disease; Mortality and Morbidity Attributable to CVD; Prevalence and Control of Cardiovascular Risk Factors; Subclinical Atherosclerosis; Ankle-Brachial Index; Economic Costs of Cardiovascular Disease; Summary; Acknowledgments; References; Chapter 2: Cardiovascular Risk Assessment; Rationale for Contemporary CV Risk Prediction
Relative Risk Versus Absolute Cardiovascular RiskTreatment Benefit Depends on Absolute Risk Rather Than Relative Risk; Multiple, Online Risk Prediction Tools for CVD are Widely Available; Current Guideline Recommendations; Current Clinical Practice Guidelines Suggest That the Indication and Intensity of Treatment Should Be Proportional to the Absolute Risk for CVD; Novel Developments in Global CVD Risk: Considering Alternative CVD Outcomes; Novel Developments in Global CVD Risk: Considering Alternative Risk Factors; Novel Serum Markers; Novel Imaging Markers; Other Risk Markers Novel Developments in Global CVD Risk: Considering Long-Term or Lifetime RiskConclusion; References; Chapter 3: The New American Prevention Guidelines: Aligning the Guidelines for Atherosclerotic Cardiovascular Risk Reduction With the Evidence; A New Approach; Major Themes; What You Need to Know; A. Heart Healthy Nutrition and Physical Activity Behaviors; B. Recommendations from the Risk Assessment Workgroup With Those Reflecting Expert Opinion Highlighted in Italics; C. Graded Recommendations for Statin Treatment to Reduce ASCVD Risk Footnotes to this Section (from the Cholesterol Guideline Report)Statin Safety Recommendations; Footnotes to this Section (from the Cholesterol Guideline Report); Monitoring Statin Therapy; Optimizing Statin Therapy; Insufficient Response to Statin Therapy; Footnotes to this Section (from the Cholesterol Guideline Report); Conclusions; References; Chapter 4: Management of High Blood Pressure; Epidemiology of Hypertension; Definition and Classification of Hypertension; Initial Evaluation of the Patient; Thresholds for Initiating Therapy; Lifestyle Modifications; Initial Drug Therapy Goal Blood Pressure for "Uncomplicated" Hypertensive PatientsGoal Blood Pressure for Hypertensive Patients with Other High-Risk Conditions; Other Issues; References; Chapter 5: Smoking and Passive Smoking; Smoking and Cardiovascular Disease; Secondhand Smoke; Trends in Cigarette Smoking; Prevention and Reduction of Tobacco Use Among Youth; Prevention and Cessation Programs for Adults; Cessation Strategies for Individuals; Behavioral Treatments; Pharmacologic Interventions; Clinical Approaches; Conclusions; References; Chapter 6: Metabolic Syndrome; History, Prevalence, and Epidemiology Definition |
| Record Nr. | UNINA-9910787804503321 |
| New York : , : demosMEDICAL, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ASPC manual of preventive cardiology / / editors, Nathan D. Wong, Ezra A. Amsterdam, and Roger S. Blumenthal
| ASPC manual of preventive cardiology / / editors, Nathan D. Wong, Ezra A. Amsterdam, and Roger S. Blumenthal |
| Pubbl/distr/stampa | New York : , : demosMEDICAL, , 2015 |
| Descrizione fisica | 1 online resource (295 p.) |
| Disciplina | 616.1/05 |
| Soggetto topico | Cardiovascular system - Diseases - Prevention |
| ISBN | 1-61705-141-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Title; Copyright; Contents; Contributors; Foreword; Preface; Acknowledgments; Share ASPC Manual of Preventive Cardiology; Chapter 1: National Burden of Cardiovascular Disease and Associated Risk Factors; Cardiovascular Disease; Mortality and Morbidity Attributable to CVD; Prevalence and Control of Cardiovascular Risk Factors; Subclinical Atherosclerosis; Ankle-Brachial Index; Economic Costs of Cardiovascular Disease; Summary; Acknowledgments; References; Chapter 2: Cardiovascular Risk Assessment; Rationale for Contemporary CV Risk Prediction
Relative Risk Versus Absolute Cardiovascular RiskTreatment Benefit Depends on Absolute Risk Rather Than Relative Risk; Multiple, Online Risk Prediction Tools for CVD are Widely Available; Current Guideline Recommendations; Current Clinical Practice Guidelines Suggest That the Indication and Intensity of Treatment Should Be Proportional to the Absolute Risk for CVD; Novel Developments in Global CVD Risk: Considering Alternative CVD Outcomes; Novel Developments in Global CVD Risk: Considering Alternative Risk Factors; Novel Serum Markers; Novel Imaging Markers; Other Risk Markers Novel Developments in Global CVD Risk: Considering Long-Term or Lifetime RiskConclusion; References; Chapter 3: The New American Prevention Guidelines: Aligning the Guidelines for Atherosclerotic Cardiovascular Risk Reduction With the Evidence; A New Approach; Major Themes; What You Need to Know; A. Heart Healthy Nutrition and Physical Activity Behaviors; B. Recommendations from the Risk Assessment Workgroup With Those Reflecting Expert Opinion Highlighted in Italics; C. Graded Recommendations for Statin Treatment to Reduce ASCVD Risk Footnotes to this Section (from the Cholesterol Guideline Report)Statin Safety Recommendations; Footnotes to this Section (from the Cholesterol Guideline Report); Monitoring Statin Therapy; Optimizing Statin Therapy; Insufficient Response to Statin Therapy; Footnotes to this Section (from the Cholesterol Guideline Report); Conclusions; References; Chapter 4: Management of High Blood Pressure; Epidemiology of Hypertension; Definition and Classification of Hypertension; Initial Evaluation of the Patient; Thresholds for Initiating Therapy; Lifestyle Modifications; Initial Drug Therapy Goal Blood Pressure for "Uncomplicated" Hypertensive PatientsGoal Blood Pressure for Hypertensive Patients with Other High-Risk Conditions; Other Issues; References; Chapter 5: Smoking and Passive Smoking; Smoking and Cardiovascular Disease; Secondhand Smoke; Trends in Cigarette Smoking; Prevention and Reduction of Tobacco Use Among Youth; Prevention and Cessation Programs for Adults; Cessation Strategies for Individuals; Behavioral Treatments; Pharmacologic Interventions; Clinical Approaches; Conclusions; References; Chapter 6: Metabolic Syndrome; History, Prevalence, and Epidemiology Definition |
| Record Nr. | UNINA-9910821507203321 |
| New York : , : demosMEDICAL, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Aspirin for the primary prevention of cardiovascular events [[electronic resource] ] : an update of the evidence / / prepared by Tracy Wolff, Therese Miller, and Stephen Ko
| Aspirin for the primary prevention of cardiovascular events [[electronic resource] ] : an update of the evidence / / prepared by Tracy Wolff, Therese Miller, and Stephen Ko |
| Autore | Wolff Tracy (Tracy A.) |
| Pubbl/distr/stampa | Rockville, MD : , : Agency for Healthcare Research and Quality, U.S. Preventive Services Task Force, , [2009] |
| Descrizione fisica | 1 online resource |
| Altri autori (Persone) |
MillerTherese
KoStephen |
| Collana | AHRQ publication |
| Soggetto topico |
Aspirin - Therapeutic use
Cardiovascular system - Diseases - Prevention |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Aspirin for the primary prevention of cardiovascular events |
| Record Nr. | UNINA-9910699067803321 |
Wolff Tracy (Tracy A.)
|
||
| Rockville, MD : , : Agency for Healthcare Research and Quality, U.S. Preventive Services Task Force, , [2009] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Biomarkers in cardiovascular diseases / / editors, Dimitris Tousoulis, Christodoulos Stefanadis
| Biomarkers in cardiovascular diseases / / editors, Dimitris Tousoulis, Christodoulos Stefanadis |
| Pubbl/distr/stampa | Boca Raton : , : CRC Press, , 2014 |
| Descrizione fisica | 1 online resource (450 p.) |
| Disciplina | 616.1075 |
| Altri autori (Persone) |
TousoulisDimitris
StefanadisChristodoulos |
| Soggetto topico |
Cardiovascular system - Diseases - Diagnosis
Cardiovascular system - Diseases - Prevention |
| ISBN |
0-429-16843-8
1-4665-8714-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | pt. 1. Classical biomarkers -- pt. 2. Novel biomarkers. |
| Record Nr. | UNINA-9910787571403321 |
| Boca Raton : , : CRC Press, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cardiovascular diabetology
| Cardiovascular diabetology |
| Pubbl/distr/stampa | London, : BioMed Central, [2002]- |
| Soggetto topico |
Diabetes - Complications
Cardiovascular system - Diseases - Complications Cardiovascular system - Diseases - Prevention Diabetes Complications Cardiovascular Diseases - complications Cardiovascular Diseases - prevention & control Cardiology Diabetes Vascular Medicine |
| Soggetto genere / forma |
Periodical
Fulltext Internet Resources. Periodicals. |
| Soggetto non controllato | Cardiovascular Diseases |
| ISSN | 1475-2840 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNISA-996212640603316 |
| London, : BioMed Central, [2002]- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
